PNC Financial Services Group’s Entrada Therapeutics TRDA Stock Holding History

PNC Financial Services Group’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.35K	Sell	1,135 -6	-0.5%	-$58	﹤0.01%	4178
2026 Q1	$14.4K	Hold	1,141	–	–	﹤0.01%	3824
2025 Q4	$11.7K	Sell	1,141 -16	-1%	-$135	﹤0.01%	3887
2025 Q3	$6.71K	Buy	+1,157	New	+$6.77K	﹤0.01%	4095
2023 Q3	–	Sell	-200	Closed	-$3.03K	–	4758
2023 Q2	$3.03K	Hold	200	–	–	﹤0.01%	4250
2023 Q1	$2.9K	Buy	+200	New	+$2.67K	﹤0.01%	4213

Other funds holding TRDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

GLA

Great Lakes Advisors Chicago, Illinois $13.1B AUM 34.09% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PNC Financial Services Group's TRDA Position: Q2 2026 in Review

PNC Financial Services Group reduced its Entrada Therapeutics (TRDA) stake by 0.53% in Q2 2026, selling an estimated $58 and leaving 1,135 shares worth $8.35K. The position accounts for ﹤0.01% of the portfolio, ranked #4178.

PNC Financial Services Group first reported a position in TRDA in Q1 2023 and has held it in 6 quarters since. The position peaked at $14.4K in Q1 2026. 42 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

PNC Financial Services Group held 1,135 shares of Entrada Therapeutics worth $8.35K as of Q2 2026.
PNC Financial Services Group sold 6 Entrada Therapeutics shares in Q2 2026, an estimated $58.
Entrada Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4178 holding.
PNC Financial Services Group first reported a position in Entrada Therapeutics in Q1 2023 and has held it in 6 quarters since.
PNC Financial Services Group's Entrada Therapeutics position peaked at $14.4K in Q1 2026.
42 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.